ID

31110

Description

A Study of Enzastaurin and Erlotinib in Patients With Solid Tumors and Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00452413

Lien

https://clinicaltrials.gov/show/NCT00452413

Mots-clés

Versions (1)
  1. 20/07/2018 20/07/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

20 juillet 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Non-Small Cell Lung Cancer NCT00452413

Anglais

Eligibility Non-Small Cell Lung Cancer NCT00452413

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. phase 1: any incurable solid malignancy, with no more than 3 prior systemic treatment regimens.
Description

Solid Neoplasm incurable | Systemic therapy Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C0280100
UMLS CUI [1,2]
C0175969
UMLS CUI [2,1]
C1515119
UMLS CUI [2,2]
C1265611
phase 2: histologic diagnosis of advanced nsclc, stage iiib with malignant pleural effusion or stage iv per american joint committee on cancer staging criteria for nsclc. patients must have failed 1 or 2 prior systemic treatment regimen(s).
Description

Non-Small Cell Lung Carcinoma Advanced TNM clinical staging | Pleural Effusion, Malignant | Systemic therapy Quantity failed

Type de données

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C3258246
UMLS CUI [2]
C0080032
UMLS CUI [3,1]
C1515119
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0231175
2. performance status of 0, 1, or 2 on the eastern cooperative oncology group (ecog) scale
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
3. prior chemotherapy must be completed at least 2 weeks prior to study enrollment, and the patient must have recovered from acute toxic effects (except alopecia) prior to enrollment.
Description

Prior Chemotherapy Completed | Toxicity Patient recovered | Exception Alopecia

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0205197
UMLS CUI [2,1]
C0600688
UMLS CUI [2,2]
C1115804
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0002170
4. prior radiotherapy is allowed to < 25% of the bone marrow prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from acute toxic effects (except alopecia) prior to enrollment.
Description

Prior radiation therapy Bone Marrow Percentage | Prior radiation therapy Completed | Toxicity Patient recovered | Exception Alopecia

Type de données

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
UMLS CUI [2,1]
C0279134
UMLS CUI [2,2]
C0205197
UMLS CUI [3,1]
C0600688
UMLS CUI [3,2]
C1115804
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0002170
5. non-measurable or measurable disease as defined by recist.
Description

Disease Non-Measurable | Measurable Disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1518373
UMLS CUI [2]
C1513041
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who
Description

Criteria Fulfill

Type de données

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
1. are unable to swallow tablets.
Description

Lacking Able to swallow Tablets

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C2712086
UMLS CUI [1,3]
C0039225
2. unable to discontinue use of carbamazepine, phenobarbital, and phenytoin.
Description

Unable to discontinue Carbamazepine | Unable to discontinue Phenobarbital | Unable to discontinue Phenytoin

Type de données

boolean

Alias
UMLS CUI [1,1]
C1548265
UMLS CUI [1,2]
C0006949
UMLS CUI [2,1]
C1548265
UMLS CUI [2,2]
C0031412
UMLS CUI [3,1]
C1548265
UMLS CUI [3,2]
C0031507
3. have previously been treated with an epidermal growth factor receptor (egfr) inhibitor, including erlotinib.
Description

Epidermal growth factor receptor inhibitor | erlotinib

Type de données

boolean

Alias
UMLS CUI [1]
C1443775
UMLS CUI [2]
C1135135
4. are receiving concurrent administration of any other antitumor therapy.
Description

Cancer treatment Other

Type de données

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205394
5. have received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry.
Description

Drugs, Non-Prescription

Type de données

boolean

Alias
UMLS CUI [1]
C0013231
Retour au début de la page

Similar models

Eligibility Non-Small Cell Lung Cancer NCT00452413

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Solid Neoplasm incurable | Systemic therapy Quantity
Item
1. phase 1: any incurable solid malignancy, with no more than 3 prior systemic treatment regimens.
boolean
C0280100 (UMLS CUI [1,1])
C0175969 (UMLS CUI [1,2])
C1515119 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
Non-Small Cell Lung Carcinoma Advanced TNM clinical staging | Pleural Effusion, Malignant | Systemic therapy Quantity failed
Item
phase 2: histologic diagnosis of advanced nsclc, stage iiib with malignant pleural effusion or stage iv per american joint committee on cancer staging criteria for nsclc. patients must have failed 1 or 2 prior systemic treatment regimen(s).
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,3])
C0080032 (UMLS CUI [2])
C1515119 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0231175 (UMLS CUI [3,3])
ECOG performance status
Item
2. performance status of 0, 1, or 2 on the eastern cooperative oncology group (ecog) scale
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy Completed | Toxicity Patient recovered | Exception Alopecia
Item
3. prior chemotherapy must be completed at least 2 weeks prior to study enrollment, and the patient must have recovered from acute toxic effects (except alopecia) prior to enrollment.
boolean
C1514457 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C1115804 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0002170 (UMLS CUI [3,2])
Prior radiation therapy Bone Marrow Percentage | Prior radiation therapy Completed | Toxicity Patient recovered | Exception Alopecia
Item
4. prior radiotherapy is allowed to < 25% of the bone marrow prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from acute toxic effects (except alopecia) prior to enrollment.
boolean
C0279134 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0279134 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C0600688 (UMLS CUI [3,1])
C1115804 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0002170 (UMLS CUI [4,2])
Disease Non-Measurable | Measurable Disease
Item
5. non-measurable or measurable disease as defined by recist.
boolean
C0012634 (UMLS CUI [1,1])
C1518373 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Criteria Fulfill
Item
patients who
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Lacking Able to swallow Tablets
Item
1. are unable to swallow tablets.
boolean
C0332268 (UMLS CUI [1,1])
C2712086 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,3])
Unable to discontinue Carbamazepine | Unable to discontinue Phenobarbital | Unable to discontinue Phenytoin
Item
2. unable to discontinue use of carbamazepine, phenobarbital, and phenytoin.
boolean
C1548265 (UMLS CUI [1,1])
C0006949 (UMLS CUI [1,2])
C1548265 (UMLS CUI [2,1])
C0031412 (UMLS CUI [2,2])
C1548265 (UMLS CUI [3,1])
C0031507 (UMLS CUI [3,2])
Epidermal growth factor receptor inhibitor | erlotinib
Item
3. have previously been treated with an epidermal growth factor receptor (egfr) inhibitor, including erlotinib.
boolean
C1443775 (UMLS CUI [1])
C1135135 (UMLS CUI [2])
Cancer treatment Other
Item
4. are receiving concurrent administration of any other antitumor therapy.
boolean
C0920425 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Drugs, Non-Prescription
Item
5. have received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial